Shire’s attention deficit hyperactivity disorder drug to sell in Japan

Shire’s attention deficit hyperactivity disorder drug to sell in Japan

March 30, 2017 Off By Dino Mustafić

Shire’s partner in Japan, Shionogi & Co has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market Intuniv, a new, once-daily non-stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD), a common psychiatric disorder in children and adolescents.

Intuniv is a selective alpha-2A adrenergic receptor agonist. With a unique mechanism of action, Intuniv represents an additional treatment option in the management of ADHD, the company said in its press release.

ADHD causes inattention, hyperactivity or impulsivity, or a combination of these symptoms and can have substantial impact on all major areas of life, including: schooling, work and employment, behaviour, social functioning, self-esteem and health.